top of page

INOLYSIS – LEADS FOR FIBROSIS

TARGETING FIBROBLASTS TO COMBAT CHRONIC INFLAMMATORY AND FIBROTIC DISEASES

NEWS

INOLYSIS has been awarded an ERC Proof of Concept Grant to support the development of a novel oral therapy targeting fibroblast-driven inflammation and fibrosis in IBD (14.07.2025).

OUR SCIENCE

INOLYSIS leverages a unique drug discovery pipeline that integrates medicinal chemistry, molecular phenotyping, in vitro and ex vivo assays, as well as in vivo efficacy and safety studies, combined with deep understanding of fibroblast biology.

WHO WE ARE

Our team combines multidisciplinary experience in biology, pathophysiology, medicinal chemistry and preclinical testing.

More than 50 million people worldwide are affected by chronic fibrotic diseases.

$75 billion per year is spent on managing healthcare expenses linked to fibrotic complications.

Over 20% of cancer patients face treatment challenges due to underlying fibrotic tissue changes.

Collaborators

OUR COLLABORATORS

Contact

CONTACT US

17 Trapezountos & Andrea Papandreou, 

Melissia 15127, Greece
Email: admin@inolysis.com

© 2025 INOLYSIS. All rights reserved.

bottom of page